Current advances, problems and prospects for vaccine-based immunotherapy in follicular non-Hodgkin's lymphoma

REFERENCES

• Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14: 520–535.
   Google Scholar
• Owaidah TM, Aljurf MD. The evolving role of monoclonal antibodies and dendritic cell therapy in hematologic malig-nancies. Hematology 2002;7:265–272.
   Google Scholar
• Dermime S, Armstrong AC, Hawkins RE, Stern PL. Cancer vaccines and immunotherapy. Br Med Bull 2002;62:149–162.
   Google Scholar
• Melief CJM. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992;58:143–175.
   Google Scholar
• Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardo11 D, Mulligan RC. Vaccinated with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulate potent, specific and long-lasting anti-tumor immu-nity. Proc Natl Acad Sci USA 1993;90:3539–3543.
   Google Scholar
• Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognised by T cells. Immunol Today 1997;18:267–268.
   Google Scholar
• Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10:281–287.
   Google Scholar
• Grey HM, Ruppert J, Vitiello A, Sidney J, Kast WM, Kubo RT, Sate A. Class I MHC-peptide interactions: structural requirement and functional implications. Cancer Serv 1995;22:37–49.
   Google Scholar
• Pieters J. MHC class II restricted antigen processing and presentation. Adv Immunol 2000;75:159–208.
   Google Scholar
• June C, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994;15: 321–331.
   Google Scholar
• Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997;9:10–16.
   Google Scholar
• Podack ER. Functional significance of two cytolytic pathways of cytotoxic lymphocytes. J Leukocyte Biol 1995;57:548–552.
   Google Scholar
• Inaba K, Steinman RM, Pack MW, Aya H, Inaba M, Sudo T, Wolpe S, Schuler G. Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 1992;175: 1157–1167.
   Google Scholar
• Nair SK, Boczkowski D, Snyder D, Gilboa E. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 1997;27: 589–597.
   Google Scholar
• Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998; 36:39–44.
   Google Scholar
• Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, TaidiB, Engelman EG, Levy R Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52–58.
   Google Scholar
• Tjoa B, Erickson S, Barren R 3rd, Ragde H, Kenny G, Boynton A, Murphy G. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 1995;27:63–69.
   Google Scholar
• Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 2003;101:977–982.
   Google Scholar
• Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:65–72.
   Google Scholar
• Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86–89.
   Google Scholar
• Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;6:332–336.
   Google Scholar
• Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA, Hwu P. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997;186:1213–1221.
   Google Scholar
• Armstrong AC, Dermime S, Allison C, Bhattacharyya T, Mulryan K, Gonzalez KR, Stern PL, Hawkins RE. Immunisa-tion with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor protective immunity and identification of an idiotype-specific T cell epitope. J Immunol 2002;168:3983–3991.
   Google Scholar
• Timmerman JM, Casper CB, Lambert SL, Syrengelas AD, Levy R. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood 2001;97:1370–1377.
   Google Scholar
• Armstrong AC, Dermime S, Mulryan K, Stern PL, Bhatta-charyya T, Hawkins RE. Adoptive transfer of anti-idiotypic T cell cure mice from disseminated B cell lymphoma. J Immunother 2004;27:227–231.
   Google Scholar
• Luna-Fineman S, Lee JE, Wesley PK, Clayberger C, Krensky AM. Human cytotoxic T-lymphocytes specific for autologous follicular lymphoma recognize immunoglobulin in a major histocompatibility complex restricted fashion. Cancer 1992;70:2181–2186.
   Google Scholar
• Wen YJ, Lim SH . T cells recognize the VI{ complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma. Eur J Immunol 1997;27: 1043–1047.
   Google Scholar
• Osterroth F, Garbe A, Fisch P, Veelken H. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malig-nant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood 2000;95:1342–1349.
   Google Scholar
• Carroll WL, Thielemans K, Dilley J, Levy R. Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Meth 1986;89:61–72.
   Google Scholar
• Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, BenikeC, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517–1526.
   Google Scholar
• Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 1997;89:3129–3135.
   Google Scholar
• Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglo-bulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 1996;93:10972–10977.
   Google Scholar
• Miller G, Pillarisetty VG, Shah AB, Lahrs S, Xing Z, DeMatteo RP. Endogenous granulocyte-macrophage colony-stimulating factor overexpression in vivo results in the long-term recruitment of a distinct dendritic cell population with enhanced immunostimulatory function. J Immunol 2002;169:2875–2885.
   Google Scholar
• George AJT, Tutt AL, Stevenson FK. Anti-idiotypic mechan-isms involved in suppression of a mouse B cell lymphoma, BCL1. J Immunol 1987;138: 628–634.
   Google Scholar
• George AJT, Folkard SG, Hamblin TJ, Stevenson FK. Idiotypic vaccination as a treatment for a B cell lymphoma. J Immunol 1988;141:2168–2174.
   Google Scholar
• King CA, Wills MR, Hamblin TJ, Stevenson FK. Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells. Cell Immunol 1993;147:411–424.
   Google Scholar
• Kaminski MS, Kitamura K, Maloney DG, Levy R. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol 1987;138:1289–1296.
   Google Scholar
• Campbell MJ, Esserman L, Levy R. Immunotherapy for established murine B cell lymphoma, combination of idiotype immunisation and cyclophosphamide. J Immunol 1988;141:3227–3233.
   Google Scholar
• Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 1990;145:1029–1036.
   Google Scholar
• Chen TT, Tao MH, Levy R. Idiotype- cytokine fusion proteins as cancer vaccines. J Immunol 1994;153:4775–4787.
   Google Scholar
• Timmerman JM, Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol 2000;164:4797–4803.
   Google Scholar
• Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self-tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Bio-technol 1999;17:253–258.
   Google Scholar
• Biragyn A, Surenhu M, Yang D, Ruffini PA, Haines BA, Klyushnenkova E, Oppenheim JJ, Kwak LW. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001;167:6644–6653.
   Google Scholar
• Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R Induction of immune responses in patients with B-cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327:1209–1215.
   Google Scholar
• Nelson EL, Li X, Hsu FJ, Kwak LW, Levy R, Clayberger C, Krensky AM. Tumor-specific, cytotoxic T-lymphocyte re-sponse after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 1996;88:580–589.
   Google Scholar
• Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimu-lating factor against lymphoma. Nat Med 1999;5:1171–1177.
   Google Scholar
• Hawkins RE, Zhu D, Ovecka M, Winter G, Hamblin TJ, Long A, Stevenson FK. Idiotypic vaccination against human B cell lymphoma, rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 1994;83:3279–3288.
   Google Scholar
• Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Im-munol 2000;18:927–974.
   Google Scholar
• Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B cell lymphoma. Nature 1993;362:755–758.
   Google Scholar
• Benvenuti F, Burrone OR, Efremov DG. Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection. Gene Ther 2000;7:605–611.
   Google Scholar
• King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J, Stevenson FK. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Natl Med 1998;4:1281–1286.
   Google Scholar
• Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Natl Med 1996;2:1038–1041.
   Google Scholar
• Syrengelas AD, Levy R DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol 1999;162:4790–4795.
   Google Scholar
• Hakim I, Levy S, Levy R. A nine-amino acid peptide from IL-lbeta augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 1996;157:5503–5511.
   Google Scholar
• Hawkins RE, Russell SJ, Marcus R, Ashworth LJ, Brissnik J, Zhang J, Winter G, Bleehen NM, Shaw MM, Williamson Let al. A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027. Hum Gene Ther 1997;8: 1287–1299.
   Google Scholar
• Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002;62:5845–5852.
   Google Scholar
• Bonnet MC, Tartaglia J, Verdier F, Kourilsky P, Lindberg A, Klein M, Moingeon P. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett 2000;74:11–25.
   Google Scholar
• Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu MZ, Scholm J. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that ex-presses human carcinoembryonic antigen. J Chin Oncol 1999;17:332–337.
   Google Scholar
• Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Chin Oncol 2000;18:3964–3973.
   Google Scholar
• Bogen B. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4 + T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasma-cytoma. Eur J Immunol 1996;26:2671–2679.
   Google Scholar
• Schultze JL. Why do B cell lymphoma fail to elicit clinically sufficient immune responses. Leuk Lymphoma 1999; 32:223–236.
   Google Scholar
• Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW. Immuniza-tion with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996;156: 3858–3865.
   Google Scholar
• Guinn BA, DeBenedette MA, Watts TH, Berinstein NL. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999;162:5003–5010.
   Google Scholar
• Goodwin RG, Din WS, Davis-Smith T, Anderson DM, Gimpel SD, Sato TA, Maliszewski CR, Brannan CI, Cope-land NG, Jenkins NA. Molecular cloning of a ligand for the inducible T cell gene 4–1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 1993;23: 2631–2641.
   Google Scholar
• van Kooten C, Banchereau J. CD4O-CD40 ligand. J Leukoc Biol 2000;67:2–17.
   Google Scholar
• Meziane el K, Bhattacharyya T, Armstrong AC, Qian C, Hawkins RE, Stern PL, Dermime S. The use of adenoviruses encoding CD4OL and/or IL-2 against B cell lymphoma. Int J Cancer 2004;111: 910–920.
   Google Scholar
• Briones J, Timmerman J, Levy R In vivo antitumor effect of CD4OL-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res 2002;62:3195–3199.
   Google Scholar
• Borrello IM, Sotomayor EM. Cancer vaccines for hematologic malignancies. Cancer Control 2002;9:138–151.
   Google Scholar
• Armstrong A, Dermime S. Developing effective cancer vaccines: design and monitoring are critical. Br J Cancer 2001;84:1433–1436.
   Google Scholar
• McCarthy H, Ottensmeier CH, Hamblin TJ, Stevenson FK. Anti-idiotype vaccines. Br J Haematol 2003;123:770–781.
   Google Scholar
• von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002;99: 3319–3325.
   Google Scholar